Infugem
Infugem is a ready-to-infuse formulation of gemcitabine, a nucleoside metabolic inhibitor (chemotherapy). It is supplied as a premixed intravenous infusion in a single-dose bag, eliminating the need for reconstitution and dilution steps before administration.
Dosage by Body Weight
Infugem must be administered intravenously under the supervision of a qualified oncologist. Dosage is highly individualized and is strictly calculated based on the patient's Body Surface Area (BSA, measured in mg/m²) and specific cancer type, rather than body weight alone. Standard infusion time is 30 minutes.
- Body Weight
- Below 5 kg
- Dose
- Not routine / Specialist determination only
- Frequency
- As directed by oncologist
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision.
- Body Weight
- 5-7 kg
- Dose
- Not routine / Specialist determination only
- Frequency
- As directed by oncologist
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision.
- Body Weight
- 8-10 kg
- Dose
- Not routine / Specialist determination only
- Frequency
- As directed by oncologist
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision.
- Body Weight
- 11-15 kg
- Dose
- Not routine / Specialist determination only
- Frequency
- As directed by oncologist
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision.
- Body Weight
- 16-20 kg
- Dose
- Not routine / Specialist determination only
- Frequency
- As directed by oncologist
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine / Specialist determination only | As directed by oncologist | Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision. |
| 5-7 kg | Not routine / Specialist determination only | As directed by oncologist | Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision. |
| 8-10 kg | Not routine / Specialist determination only | As directed by oncologist | Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision. |
| 11-15 kg | Not routine / Specialist determination only | As directed by oncologist | Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision. |
| 16-20 kg | Not routine / Specialist determination only | As directed by oncologist | Safety and effectiveness in pediatric patients have not been established. Dosage must be calculated based on Body Surface Area (BSA) under strict oncologist supervision. |
Formulation
Purpose
Treatment of advanced or metastatic ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer.
Generic Name
Gemcitabine in 0.9% Sodium ChlorideScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.